List of Excipients in Branded Drug ONDANSETRON

Generic Drugs Containing ONDANSETRON

Company	Ingredient	NDC	Excipient
PAI Holdings LLC dba PAI Pharma	ondansetron	0121-0882	ANHYDROUS CITRIC ACID
PAI Holdings LLC dba PAI Pharma	ondansetron	0121-0882	FRUCTOSE
PAI Holdings LLC dba PAI Pharma	ondansetron	0121-0882	HYDROXYETHYL CELLULOSE
PAI Holdings LLC dba PAI Pharma	ondansetron	0121-0882	SODIUM BENZOATE

What are the Most Frequently-Used Excipients in ONDANSETRON?

# Of NDCs	Excipient
1	ACETIC ACID
31	ANHYDROUS CITRIC ACID
10	ANHYDROUS LACTOSE
162	ASPARTAME

Last updated: August 29, 2026

Ondansetron is a mature, multisource antiemetic with limited active-ingredient patent protection and substantial room for excipient-led differentiation. The strongest commercial opportunities are orally disintegrating tablets, pediatric liquids, ready-to-use injections, preservative-free presentations, taste-masked products, and formulations designed for global markets with limited cold-chain or administration infrastructure. Regulatory execution, palatability, dose flexibility, supply reliability, and device usability matter more than new chemical entity exclusivity.

Ondansetron Excipient Strategy and Commercial Opportunities

What is the commercial status of ondansetron?

Ondansetron is a selective 5-HT3 receptor antagonist used to prevent nausea and vomiting associated with chemotherapy, radiotherapy, and surgery. The reference product, Zofran, was developed by GlaxoSmithKline and commercialized in tablets, orally disintegrating tablets, oral solution, and injection.

The market is predominantly generic. Ondansetron products are approved through abbreviated new drug applications under the FDA's 505(j) pathway, while reformulated products with meaningful delivery or clinical differences may qualify for a 505(b)(2) application. FDA-approved dosage forms include:

Dosage form	Primary commercial use	Excipient-led opportunity
Immediate-release tablet	Outpatient and institutional use	Low-cost, low-weight, robust tablets
Orally disintegrating tablet	Patients unable to swallow	Fast disintegration, taste masking, moisture control
Oral solution	Pediatric and geriatric use	Sugar-free, alcohol-free, preservative optimization
Injection	Perioperative and oncology settings	Ready-to-use, preservative-free, compatibility and stability
Potential oral film or powder	Emerging delivery platform	Waterless dosing, portability, dose flexibility

The market's core demand is generic and price-sensitive. Product differentiation must therefore improve administration, adherence, safety, supply continuity, or institutional workflow rather than simply reproduce the reference formulation.

What patents protect ondansetron?

The principal ondansetron compound patents have expired, eliminating the original small-molecule patent barrier in the United States and major regulated markets. Zofran's commercial exclusivity ended years ago, and multiple manufacturers now supply generic ondansetron.

The relevant intellectual-property position is divided into four categories:

IP category	Current strategic relevance
Original ondansetron compound patents	Expired
Original tablet and solution patents	Expired or commercially immaterial
Orally disintegrating tablet technology	May involve platform patents, but does not create broad ondansetron exclusivity
New formulations, devices, or methods of use	Potentially protectable if they provide a non-obvious technical or clinical benefit

A commercial diligence review should distinguish between patents covering ondansetron itself and patents covering a specific excipient system, manufacturing process, dosage form, or administration method. A patent on a proprietary fast-dissolving matrix would not necessarily prevent conventional ondansetron tablets or injections.

The FDA Orange Book is the primary source for listed patents and regulatory exclusivity associated with approved drug products. For a mature generic product such as ondansetron, the principal commercial risk is generally not an active compound patent but the ability to secure ANDA approval, maintain manufacturing economics, and meet quality requirements. [1]

When does ondansetron lose exclusivity?

Ondansetron's original market exclusivity has already expired. Generic entry began in the United States in the early 2000s after expiration of the relevant Zofran patent and regulatory exclusivity periods.

There is no broad current exclusivity period comparable to the exclusivity attached to a new chemical entity. A reformulated ondansetron product could receive limited regulatory exclusivity only if it meets the requirements of an applicable FDA pathway, such as a new clinical investigation supporting a 505(b)(2) product or a qualifying orphan indication. A new excipient combination alone normally does not create market exclusivity.

The commercial planning consequence is direct: an ondansetron product should be modeled as a competitive generic or specialty reformulation, not as a protected branded product, unless the sponsor owns enforceable formulation, device, or method-of-use rights.

What excipients are used in ondansetron tablets?

Immediate-release ondansetron tablets typically use conventional direct-compression or wet-granulation excipients. Specific compositions differ by manufacturer and strength.

Common excipient classes include:

• Lactose monohydrate or another diluent
• Microcrystalline cellulose for compactibility
• Pregelatinized starch or other binder-disintegrant systems
• Crospovidone, sodium starch glycolate, or croscarmellose sodium
• Colloidal silicon dioxide as a glidant
• Magnesium stearate as a lubricant
• Hypromellose, polyethylene glycol, talc, titanium dioxide, and colorants in film coatings

The formulation objective is usually low-cost manufacture with adequate hardness, rapid disintegration, low friability, and acceptable dissolution. Ondansetron doses are relatively small, so blend uniformity and segregation control are important. Excessive lubricant levels can slow dissolution, while high levels of hygroscopic disintegrants can damage stability during storage.

Commercial opportunities include:

1. A robust low-cost tablet for high-volume generic tenders.
2. A smaller tablet for pediatric or geriatric administration.
3. A colorant-free or titanium-dioxide-free product for markets with tighter excipient restrictions.
4. A lactose-free product for patients or markets avoiding lactose.
5. A tablet with improved humidity stability for tropical climates.

These opportunities are operational rather than patent-driven. The sponsor must demonstrate pharmaceutical equivalence and bioequivalence where required, while controlling extractables, impurities, dissolution, and stability.

What excipients are used in ondansetron orally disintegrating tablets?

Ondansetron orally disintegrating tablets, including products marketed under the Zofran ODT name, are designed to disintegrate on the tongue without water. They require a different excipient strategy from conventional tablets.

Typical excipient functions include:

Function	Common excipient options
Bulking and mouthfeel	Mannitol, lactose, microcrystalline cellulose
Disintegration	Crospovidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose
Taste masking	Polymer coating, ion-exchange resin, cyclodextrin, flavor system
Flow improvement	Colloidal silicon dioxide
Lubrication	Magnesium stearate or sodium stearyl fumarate
Sweetening	Aspartame, sucralose, acesulfame potassium, saccharin
Flavor	Strawberry, berry, mint, or other pediatric-oriented flavors

Taste masking is the central technical problem. Ondansetron has a bitter taste, and rapid dissolution increases exposure of the active ingredient to taste receptors. A formulation that disintegrates quickly but fails palatability testing is unlikely to compete effectively in pediatric or outpatient markets.

Key development variables include:

• Particle size and surface area of ondansetron
• Coating efficiency for taste-masked particles
• Drug loading and content uniformity
• Disintegration time under low saliva volume
• Tablet friability during blister packaging
• Moisture sensitivity
• Sweetener and flavor compatibility
• Aspartame labeling requirements for patients with phenylketonuria

A high-value product could combine fast disintegration with a strong taste profile, unit-dose packaging, and improved resistance to humidity. The commercial advantage is strongest in pediatric oncology, emergency departments, ambulances, and home-care settings.

What excipients are used in ondansetron oral solutions?

Ondansetron oral solutions must balance solubility, chemical stability, taste, preservative performance, and pediatric acceptability. Reference and generic solutions may contain combinations of:

• Purified water
• Citric acid and sodium citrate for pH control
• Sorbitol or another sweetening and bulking agent
• Sodium benzoate or another preservative
• Flavoring agents
• Colorants
• Solubilizers or viscosity modifiers

The exact composition differs among approved products and should be confirmed against the current FDA-approved labeling. DailyMed provides product-specific ingredient declarations and is the preferred source for formulation-level comparison. [2]

The main commercial opportunities are:

Sugar-free pediatric solution

A sugar-free product can target hospitals, pediatric clinics, and patients requiring reduced sugar exposure. Sorbitol, sucralose, or other non-sucrose systems may be used, but excessive polyol content can create gastrointestinal tolerability concerns.

Alcohol-free formulation

An alcohol-free product is commercially attractive for pediatric use and for markets with strict excipient policies. The formulation must preserve solubility, taste, and microbial control without relying on ethanol.

Improved taste and reduced aftertaste

Flavor systems should be evaluated with pediatric-relevant taste panels. Ondansetron's bitterness can persist after swallowing, making aftertaste control as important as initial taste.

Low-volume, concentrated dosing

A more concentrated solution can reduce the volume administered to children. The tradeoff is higher local taste intensity and greater dose-measurement risk. Oral syringes, calibrated cups, and clear concentration labeling are important risk controls.

Preservative strategy

Preservatives can create regulatory and tolerability concerns. A multidose product may need antimicrobial protection, while a unit-dose presentation may support a preservative-free design at higher packaging cost.

What excipients are used in ondansetron injection?

Ondansetron injection is commonly formulated as an aqueous solution containing sodium chloride and pH-adjusting agents. Product-specific formulations may contain citric acid, sodium citrate, or other buffering components. Some presentations are preservative-free, while others may use a preservative depending on container and product design. [2,3]

The highest-value injection opportunities are operational:

• Ready-to-use prefilled syringes
• Small-volume bags
• Pharmacy bulk packages
• Preservative-free presentations
• Latex-free container systems
• Improved compatibility with infusion fluids
• Enhanced protection from light and temperature excursions

Injection development requires control of pH, osmolality, visible and subvisible particles, container-closure integrity, sterilization, extractables and leachables, and compatibility with common intravenous fluids. FDA labeling identifies administration restrictions and dilution requirements, which can create practical differentiation for a ready-to-use product. [3]

A prefilled syringe can reduce preparation time and medication errors in perioperative settings. Its commercial success depends on device cost, terminal sterilization or aseptic processing capability, and procurement acceptance. The product may compete more on hospital workflow than on active pharmaceutical ingredient price.

What formulation patents could protect a new ondansetron product?

A new ondansetron product may obtain patent protection for a narrow technical solution rather than for the active ingredient. Potential claim areas include:

• A defined taste-masking coating or matrix
• A specific orally disintegrating composition
• A moisture-resistant packaging and formulation combination
• A stable concentrated oral solution
• A preservative-free multidose system
• A prefilled syringe or autoinjector configuration
• A controlled-release formulation
• A combination product with another antiemetic
• A manufacturing process that improves impurity control or yield

Patent strength depends on claim breadth, prior art, enablement, written description, and the ability to show unexpected performance. A claim reciting familiar excipients in routine concentrations is vulnerable. Stronger protection usually requires a defined composition linked to measurable results such as faster disintegration, improved taste scores, enhanced stability, or reduced impurity formation.

The most defensible strategy is often a layered portfolio:

1. Composition claims.
2. Manufacturing-process claims.
3. Packaging or container-closure claims.
4. Device claims.
5. Method-of-use claims where clinically supported.

Are there Paragraph IV challenges to ondansetron?

Ondansetron has been subject to generic competition for many years, and historical ANDA filings likely included patent certifications against expired or non-blocking Zofran patents. Current commercial analysis should focus on whether any listed patent remains enforceable and relevant to the specific reference-listed drug and dosage form.

A Paragraph IV certification can trigger litigation under the Hatch-Waxman Act, but an old ondansetron product generally offers limited litigation value unless a sponsor has obtained later patents covering a specific formulation, device, or method of use. The likely generic-entry scenario for a conventional ondansetron tablet or injection is immediate competition after approval, not a prolonged patent hold.

No broad biosimilar risk exists because ondansetron is a synthetic small molecule, not a biologic. The relevant competitors are ANDA holders, branded generics, contract manufacturers, and differentiated 505(b)(2) sponsors.

What is the FDA regulatory status of ondansetron?

Ondansetron is an FDA-approved prescription drug available in several dosage forms. Conventional generic tablets, oral solutions, orally disintegrating tablets, and injections are generally reviewed through ANDA pathways when they match the reference product in dosage form, strength, route, and relevant performance characteristics. [1,4]

A sponsor may consider 505(b)(2) when the product introduces a meaningful change, such as:

• A new route of administration
• A novel delivery system
• A new dosage regimen
• A formulation requiring clinical bridging
• A combination product
• A new indication supported by clinical data

The 505(b)(2) route is more expensive and slower than an ANDA but can support differentiation and, in limited circumstances, regulatory exclusivity. The sponsor must assess whether the reformulation produces a sufficient clinical or delivery benefit to justify the additional development burden.

How strong is the ondansetron patent estate?

The patent estate for conventional ondansetron products is weak from a market-exclusion perspective because the foundational compound protection has expired and the product is widely available from generic manufacturers.

Its remaining IP value is concentrated in product-specific innovations:

Asset	Patent strength
Conventional immediate-release tablet	Low
Standard oral solution	Low
Standard injection	Low to moderate, depending on device and packaging
Taste-masked ODT	Moderate if performance is unexpected
Oral film or waterless dosage form	Moderate to high if technically differentiated
Novel combination therapy	Depends on clinical and formulation claims
Manufacturing process	Moderate if difficult to design around

Freedom-to-operate analysis should cover excipient suppliers, taste-masking technologies, blister systems, film-forming polymers, prefilled syringe platforms, and third-party manufacturing processes. Platform patents can create risk even when no ondansetron-specific patent is active.

Which companies are competing in ondansetron?

Competition includes the reference-product owner, large generic manufacturers, specialty generic companies, hospital suppliers, and contract development and manufacturing organizations. Major generic competitors have historically included Teva, Sandoz, Mylan, Dr. Reddy's, Hikma, and other regional suppliers, although product availability varies by dosage form and jurisdiction.

The competitive landscape is segmented:

• Retail generic tablets compete on price and wholesaler access.
• ODT products compete on palatability and convenience.
• Oral solutions compete on pediatric usability and excipient profile.
• Injections compete on supply continuity, presentation, and hospital workflow.
• Specialty products compete on delivery technology and formulation IP.

A new entrant should avoid competing solely on tablet price unless it has a structural cost advantage, reliable API supply, and access to government or institutional tenders.

What commercial opportunities exist for ondansetron excipient innovation?

The most credible opportunities are summarized below.

Opportunity	Target customer	Principal development barrier
Sugar-free pediatric solution	Pediatric and outpatient markets	Taste and preservative system
Alcohol-free solution	Pediatric and global markets	Solubility and antimicrobial control
Taste-masked ODT	Children, elderly patients, oncology	Bitterness and humidity sensitivity
Waterless oral film	Mobile and home use	Dose uniformity and film robustness
Preservative-free injection	Hospitals and perioperative care	Sterility, packaging, and shelf life
Prefilled syringe	Hospitals and emergency care	Device cost and compatibility
Tropical-stable tablet or ODT	Emerging markets	Moisture ingress and packaging
Flexible-dose pediatric product	Caregivers and hospitals	Dosing accuracy and labeling

The strongest opportunity is a product that combines multiple benefits without creating a difficult regulatory package. For example, a unit-dose, sugar-free, alcohol-free, taste-masked oral formulation with an oral syringe could target pediatric care. A ready-to-use preservative-free injection could target hospitals where preparation time and medication safety affect purchasing decisions.

What manufacturing and supply barriers affect ondansetron?

Ondansetron itself is widely available, so manufacturing barriers usually arise from formulation and packaging rather than API scarcity. Key risks include:

• API particle-size variability
• Blend segregation at low dose
• Coating uniformity for taste-masked particles
• Moisture uptake in ODTs
• Preservative effectiveness in oral liquids
• Container-closure integrity
• Sterile filling capacity for injections
• Extractables and leachables from plastic systems
• Global excipient qualification
• Supplier concentration for specialized polymers or films

A dual-source strategy should cover API, critical excipients, packaging components, and contract manufacturing. Excipient changes can affect dissolution, bioequivalence, stability, and regulatory filing commitments. A formulation designed around a single proprietary polymer or coating process may create supply and licensing exposure.

What litigation and settlement risks affect ondansetron?

Historical Zofran patent litigation was associated with generic entry and patent certifications. For a current ondansetron launch, the relevant risk is product-specific. A sponsor should review FDA Orange Book listings, USPTO records, patent-family status, ANDA litigation databases, and any license or settlement terms tied to a particular formulation.

Settlement agreements involving expired ondansetron patents generally have limited current value. A later patent covering an ODT, oral film, combination, or device could create a new litigation profile. The key questions are whether the patent is listed for the relevant reference product, whether the claims cover the proposed formulation, and whether a design-around is technically and commercially feasible.

How does ondansetron compare with competing antiemetics?

Ondansetron competes with granisetron, palonosetron, dolasetron where available, metoclopramide, prochlorperazine, and newer combination regimens. Its strengths are broad clinical familiarity, multiple dosage forms, generic pricing, and established hospital use.

Product	Competitive strength	Excipient-led opportunity
Ondansetron	Low cost and broad availability	Pediatric, ODT, injection, and convenience formats
Granisetron	Longer dosing intervals in some uses	Sustained-release or patch delivery
Palonosetron	Longer half-life and oncology positioning	Device and combination products
Metoclopramide	Prokinetic activity	Different safety and tolerability profile
Aprepitant-based regimens	Strong chemotherapy positioning	Combination products rather than simple excipient reformulation

Ondansetron's commercial advantage is greatest where rapid access, low cost, and flexible administration matter. Its limitation is the lack of meaningful composition-of-matter exclusivity.

Key Takeaways

• Ondansetron is a mature generic market with expired foundational patent protection.
• Excipient innovation is most valuable in ODTs, pediatric liquids, oral films, and ready-to-use injections.
• Taste masking, moisture protection, preservative selection, and dose accuracy are the main formulation challenges.
• Sugar-free, alcohol-free, preservative-free, and tropical-stable products offer credible commercial differentiation.
• Conventional tablets and solutions have weak patent potential unless supported by unexpected technical performance.
• A 505(b)(2) strategy may be appropriate for a novel delivery system, device, route, or clinically differentiated formulation.
• No biosimilar risk applies because ondansetron is a synthetic small molecule.
• Generic launch risk is high for standard dosage forms and lower for technically differentiated products.
• Manufacturing, packaging, and hospital workflow can provide stronger commercial barriers than active-ingredient patents.
• FDA Orange Book, DailyMed, approved labels, USPTO records, and ANDA litigation records should anchor product-specific diligence.

FAQs About Ondansetron Excipient and Commercial Strategy

Can ondansetron be formulated without lactose?

Yes. Lactose can be replaced with mannitol, microcrystalline cellulose, starch-based excipients, or other suitable diluents. The substitute must preserve blend uniformity, hardness, dissolution, stability, and bioequivalence.

Is an ondansetron oral film commercially attractive?

It can be attractive where waterless administration and portability matter. The main technical risks are dose uniformity, bitterness, film mechanical strength, moisture sensitivity, and packaging cost.

Can a sugar-free ondansetron product receive patent protection?

A sugar-free formulation can be patented only if the claims meet novelty and non-obviousness requirements. Sugar removal alone is unlikely to support strong protection without an unexpected technical result.

Does ondansetron require cold-chain distribution?

Standard ondansetron tablets, oral solutions, and injections are generally stored under labeled controlled room-temperature conditions rather than refrigerated distribution. Exact requirements depend on the approved product and packaging system. [2,3]

What is the best ondansetron product for hospital contracting?

A ready-to-use, preservative-free injection or prefilled syringe can offer greater contracting differentiation than a conventional vial. Procurement value depends on price, supply reliability, compatibility, workflow reduction, and medication-error controls.

References

1. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
2. National Library of Medicine. (2024). DailyMed: Ondansetron product labeling and inactive ingredients. https://dailymed.nlm.nih.gov/dailymed/
3. U.S. Food and Drug Administration. (2023). Zofran and ondansetron injection prescribing information. https://www.accessdata.fda.gov/
4. U.S. Food and Drug Administration. (2024). Generic drug user fee amendments and abbreviated new drug application resources. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/